These innovative molecules represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://umarztpl422360.ltfblog.com/37710171/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide